The Lowest Dose of Mounjaro and Why It Exists

Step 1: Why treatment opens at 2.5mg

The 2.5mg weekly dose exists for one reason: to reduce the likelihood of early side effects, particularly the nausea, indigestion and fatigue that can occur when the gut first encounters a GIP and GLP-1 receptor agonist. Mounjaro works by activating two hormone pathways involved in appetite signalling and gastric emptying, and that mechanism, while effective, takes adjustment. Starting lower buys the body time.

This is worth understanding clearly because plenty of people arrive expecting 2.5mg to produce noticeable weight loss within the first month. It rarely does, and that is by design. The NHS medicines page for tirzepatide confirms that the lowest dose of tirzepatide is the starting point, not the therapeutic target. Once tolerability is established, the prescriber will typically move the dose upward.

If you are curious whether staying on the lowest dose of Mounjaro is an option in particular circumstances, the clinical picture is more nuanced than a flat yes or no — a prescriber is the right person to make that call.

Step 2: The four-week titration rhythm and what drives it

After the opening four weeks at 2.5mg, the licensed schedule moves to a lower dose of Mounjaro at 5mg for another four weeks, and then upward through 7.5mg, 10mg, 12.5mg and 15mg, each step approximately one month apart. The full Mounjaro dosage levels are set out clearly in the medicine's Summary of Product Characteristics on the eMC, which is worth bookmarking as the authoritative reference for storage details, contraindications and precise dosing language.

In practice, the pace can shift. If nausea or other gastrointestinal effects are significant at a given dose, a prescriber may recommend staying at that level for another cycle before moving on. The question is always tolerability versus progress, weighed together. Most people manage the step-up schedule without major difficulty; a smaller number take longer to reach higher doses. Both patterns are well within normal clinical experience.

A question our prescribers hear most weeks is whether a slower climb means something is wrong. It does not. The goal is the highest dose you tolerate well, arrived at in a way that keeps the treatment sustainable.

Step 3: Where the actual weight-loss evidence begins

The pivotal SURMOUNT-1 trial (published in the New England Journal of Medicine) randomised 2,539 adults with obesity and tested tirzepatide at 5mg, 10mg and 15mg against placebo over 72 weeks. Average body-weight reductions at those doses were meaningful and clinically significant, with the 15mg group seeing around 20–21% average reduction. The 2.5mg dose was not tested as a maintenance dose in that trial; it was not designed to be one.

NICE's appraisal of tirzepatide (TA1026), published in December 2024, reflects this: the recommendation covers adults who meet the eligibility criteria and are being titrated toward therapeutic doses, not those maintained indefinitely at the lowest level. If you want to understand how Mounjaro fits into the wider weight-management picture, including what eligibility looks like in practice, that context matters.

One contextual note on cost: the medicine's price varies by dose and provider. For a clear picture of what a full treatment package through a regulated UK service involves, the treatment options and pricing page explains what is included at each stage.

Step 4: What clinical review looks like before and after each dose

At nume, no pen is dispatched without a prescriber reading the consultation. That applies at the start and at every repeat, the person checking your answers before the first 2.5mg pen leaves the pharmacy is the same category of clinician who reviews whether you are ready to move to 5mg. Evidence of current treatment and tolerability is reviewed before any dose increase is confirmed.

Orders placed before 12pm on weekdays are reviewed and, where clinically suitable, dispatched the same day with free next-working-day delivery. So if you place an order at 11am on a Tuesday, the pen can be with you on Wednesday, useful to know if you are timing a dose change around the week. For a broader overview of how the service works, the about us page covers the pharmacy's GPhC registration and clinical structure.

If you have questions about your specific situation before starting a consultation, the team is available seven days a week. The FAQs also cover a range of common questions about the process.